Table 2

Plasmodium falciparum kelch 13 Mutations, 9 Countries in Africa, 2014–2018

Sarah E. Schmedes¹, Dhruviben Patel¹, Simran Dhal, Julia Kelley, Samaly S. Svigel, Pedro Rafael Dimbu, Adicatou-Laï Adeothy, Gauthier Mesia Kahunu, Papy Mandoko Nkoli, Abdoul Habib Beavogui, Simon Kariuki, Don P. Mathanga, Ousmane Koita, Deus Ishengoma, Ally Mohamad, Moonga Hawela, Leah F. Moriarty, Aaron M. Samuels, Julie Gutman, Mateusz M. Plucinski, Venkatachalam Udhayakumar, Zhiyong Zhou, Naomi W. Lucchi, Meera Venkatesan, Eric S. Halsey, and Eldin Talundzic

Author affiliations: Association of Public Health Laboratories, Silver Spring, Maryland, USA (S.E. Schmedes); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.E. Schmedes, D. Patel, S.S. Svigel, A.M. Samuels, J. Gutman, M.M. Plucinski, V. Udhayakumar, Z. Zhou, N.W. Lucchi, E. Talundzic); Williams Consulting LLC, Baltimore, Maryland, USA (D. Patel); The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta (S. Dahl); CDC Foundation, Atlanta (J. Kelley); National Malaria Control Program, Ministry of Health, Luanda, Angola (P.R. Dimbu); National Malaria Control Program, Ministry of Health, Porto-Novo, Benin (A.-L. Adeothy); University of Kinshasa, Kinshasa, Democratic Republic of the Congo (G.M. Kahunu); National Institute of Biomedical Research, Kinshasa (P.M. Nkoli); Maferinyah Rural Health Research Center, Mafèrinyah, Guinea (A.H. Beavogui); Kenya Medical Research Institute, Centre for Global Health Research, Kisumu, Kenya (S. Kariuki); University of Malawi College of Medicine, Blantyre, Malawi (D.P. Mathanga); University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali (O. Koita); Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA (D. Ishengoma); National Institute for Medical Research, Tanga Research Centre, Dar es Salaam, Tanzania (D. Ishengoma, A. Mohamad); Monash University Faculty of Pharmaceutical Sciences, Melbourne, Australia (D. Ishengoma); National Malaria Elimination Centre, Lusaka, Zambia (M. Hawela); US President’s Malaria Initiative, Centers for Disease Control and Prevention, Atlanta (L.F. Moriarty, M.M. Plucinski, E.S. Halsey); US President’s Malaria Initiative, US Agency for International Development, Washington, DC, USA (M. Venkatesan)

Main Article

Summary of antimalarial therapeutic efficacy studies, 9 countries in Africa, 2002–2007*

Country	Sites	Treatments studied	Age of patients enrolled	Year	Total no. samples			ACTs introduced
Country	Sites	Treatments studied	Age of patients enrolled	Year	D0 + DF	D0	DF	ACTs introduced
Angola	Benguela, Zaire, Lunda Sul	AL, ASAQ, DP	6 mo–12 y	2015	379	379	0	2005
				2017	76	38	38	2005
Benin	Klouanmey, Djougou	AL	6–59 mo	2017	194	175	19	2004
DRC	Kabondo, Kapolowe, Rutshuru, Mikalayi, Kimpese	AL, ASAQ, DP	6–59 mo	2017–2018	633	317	316	2006
Guinea	Maferinyah, Labè	AL	6–59 mo	2016	432	409	23	2004–2005
Kenya	Siaya County	AL, DP	6–59 mo	2016–2017	417	325	92	2006
Malawi	Machinga, Nkhotakota, Karonga	AL, ASAQ	6–59 mo	2014	27	8	19	2007
Mali	Dioro, Sèlinguè	AL, ASAQ	2–59 mo	2015–2016	410	320	90	2006
Tanzania	Kibaha, Ujiji, Mkuzi, Mlimba	AL	6 mo–10 y	2016	417	345	72	2006
Zambia	Gwembe, Katete, Mansa	AL, DP	>6 mo	2016	263	263	0	2002
Total					3,248	2,579	669

*ACTs, artemisinin-based combination therapies; AL, artemether/lumefantrine; ASAQ, artesunate/amodiaquine; D0, day of enrollment (pretreatment); DF, day of failure; DP, dihydroartemisinin/piperaquine; DRC; Democratic Republic of the Congo.

Main Article

¹These authors contributed equally to this article.

Page created: April 28, 2021

Page updated: June 16, 2021

Page reviewed: June 16, 2021

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.